Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.76 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.54 |
| ▸ | RXRA | P19793 | 5/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.54 |
| ▸ | RARA | P10276 | 4/20 | 0.54 |
| ▸ | RARB | P10826 | 4/20 | 0.54 |
| ▸ | RARG | P13631 | 4/20 | 0.54 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.54 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.54 |
| ▸ | BLM | P54132 | 3/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.54 |
| ▸ | RXRB | P28702 | 2/20 | 0.54 |
| ▸ | RXRG | P48443 | 2/20 | 0.54 |
| ▸ | RORC | P51449 | 2/20 | 0.54 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.54 |
| ▸ | HTR2B | P41595 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17769829 | 1.00 | MAPT (0.76) | MAPTALOX15ALDH1A1RXRACYP3A4 | |
| SCHEMBL7088911 | 1.00 | MAPT (0.76) | MAPTALOX15ALDH1A1RXRACYP3A4 | |
| SCHEMBL4389183 | 1.00 | MAPT (0.76) | MAPTALOX15ALDH1A1RXRACYP3A4 | |
| SCHEMBL5905823 | 0.90 | MAPT (0.74) | MAPTALOX15ALDH1A1RXRACYP3A4 | |
| SCHEMBL10067470 | 0.89 | MAPT (0.72) | MAPTALOX15ALDH1A1RXRACYP3A4 | |
| SCHEMBL3389048 | 0.89 | MAPT (0.72) | MAPTALOX15ALDH1A1RXRACYP3A4 | |
| SCHEMBL1717832 | 0.88 | MAPT (0.71) | MAPTALOX15ALDH1A1RXRACYP3A4 | |
| SCHEMBL20622733 | 0.88 | MAPT (0.57) | MAPTALOX15ALDH1A1RXRACYP3A4 | |
| SCHEMBL25378972 | 0.87 | MAPT (0.81) | MAPTALOX15ALDH1A1RXRACYP3A4 | |
| SCHEMBL161114 | 0.87 | MAPT (0.81) | MAPTALOX15ALDH1A1RXRACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3221284-A2 | 13-CIS-RAMBA RETINAMIDES THAT DEGRADE MNKS FOR TREATING CANCER | University of Maryland, Baltimore (US) | 2017-09-27 | — | — | EP | disclosed |
| WO-2016081589-A2 | 13-CIS-RAMBA RETINAMIDES THAT DEGRADE MNKS FOR TREATING CANCER | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2016-05-26 | — | — | WO | disclosed |
| US-8481011-B2 | Use of polyunsaturated compounds as whitening agents | PIERRE FABRE DERMO-COSMETIQUE (FR) | 2013-07-09 | — | — | US | disclosed |
| EP-1734944-B1 | 4-OXO-FENRETINIDE, ADMINISTERED ALONE AND IN COMBINATION WITH FENRETINIDE, AS PREVENTIVE AND THERAPEUTIC AGENT FOR CANCER | FOND IRCCS ISTITUTO NAZ DEI TUMORI (IT) | 2012-06-13 | — | — | EP | disclosed |
| US-20090304614-A1 | Use of Polyunsaturated Compounds as Whitening Agents | PIERRE FABRE DERMO-COSMETIQUE (FR) | 2009-12-10 | — | — | US | disclosed |
| US-7169813-B2 | 4-oxo-fenretinide, administered alone and in combination with fenretinide, as preventive and therapeutic agent for cancer | Fondazione IRCCS “Istituto Nazionale Dei Tumori” (IT) | 2007-01-30 | — | — | US | disclosed |
| EP-1734944-A1 | 4-OXO-FENRETINIDE, ADMINISTERED ALONE AND IN COMBINATION WITH FENRETINIDE, AS PREVENTIVE AND THERAPEUTIC AGENT FOR CANCER | ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI (IT) | 2006-12-27 | — | — | EP | disclosed |
| US-20060264514-A1 | 4-OXO-FENRETINIDE, ADMINISTERED ALONE AND IN COMBINATION WITH FENRETINIDE, AS PREVENTIVE AND THERAPEUTIC AGENT FOR CANCER | FONDAZIONE IRCCS "ISTITUTO NAZIONALE DEI TUMORI" (IT) | 2006-11-23 | — | — | US | disclosed |
| WO-2005092314-A1 | 4-OXO-FENRETINIDE, ADMINISTERED ALONE AND IN COMBINATION WITH FENRETINIDE, AS PREVENTIVE AND THERAPEUTIC AGENT FOR CANCER | ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEL TUM (IT) | 2005-10-06 | — | — | WO | disclosed |
| EP-0498883-A4 | 3-SUBSTITUTED AND 3,3-DISUBSTITUTED 4-OXORETINOIC ACIDS AND THEIR ESTERS | — | 1993-03-10 | — | — | EP | disclosed |
| EP-0498883-A1 | 3-SUBSTITUTED AND 3,3-DISUBSTITUTED 4-OXORETINOIC ACIDS AND THEIR ESTERS | SOUTHERN RESEARCH INSTITUTE (US) | 1992-08-19 | — | — | EP | disclosed |
| US-5124083-A | Anticarcinogenic agents | SOUTHERN RESEARCH INSTITUTE (US) | 1992-06-23 | — | — | US | disclosed |
| WO-1992004432-A1 | 3-SUBSTITUTED AND 3,3-DISUBSTITUTED 4-OXORETINOIC ACIDS AND THEIR ESTERS | SOUTHERN RESEARCH INSTITUTE (US) | 1992-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264514-A1 | 4-OXO-FENRETINIDE, ADMINISTERED ALONE AND IN COMBINATION WITH FENRETINIDE, AS PREVENTIVE AND THERAPEUTIC AGENT FOR CANCER | NR2E3, NR4A3, NR4A2 | MAPT 3897/4885ALOX15 1596/4885ALDH1A1 719/4885 |
| US-20090304614-A1 | Use of Polyunsaturated Compounds as Whitening Agents | FASN, ALOX5, ALOX15B | MAPT 2405/4885ALOX15 5/4885ALDH1A1 277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.